Molnupiravir EIDD-2801（API） CAS NO.2349386-89-4

Anqing World Chemical Co.,Ltd.Mainly responsible for the development of domestic and international business.In 2015,Haikang established the second branch,called Anqing Xuanyu Medical&Technology Co., Ltd, it is an R&D company that selects reliable technology and cooperative research partner for our corporation.

Haikang is committed to R&D,manufacture and sales of chemical raw materials API and intermediates.Meanwhile,we also provide services like product customization,process improvement,achievement transfer, etc. Through years effort,Haikang has made remarkable achievements in the R&D and production of anti-virus,antidiabetic,antineoplastic,beauty and whitening resist oxidation series API and intermediates.The main products are Ganciclovir, Sitagliptin, Vildagliptin, Silodosin and Imatinib API and Intermediates.

To deal with increasingly competition,Haikang adheres to “Customer is First,Technology is Leading,Quality is Life,Honesty for Developing”,and optimizes actively the products and better service to customers.

Early research is UniversityofNorthCarolina EIDD - 2801 VanderbiltUniversity and EmoryUniversity cooperative research and development.Merck will partner with RidgebackBiotherapeutics, a small biotech company that has a license under the EIDD-2801 development license, to develop the drug Chemicalbook.Experiments in human cells and mice have shown that EIDD-2801, as a broad-spectrum oral antiviral agent, has a prophylactic or therapeutic effect against a variety of coronaviruses :SARS-CoV,MERS-CoV, and anti-SARS-CoV-2.

Molnupiravir (Molnupiravir), also known as EIDD-2801/MK4482, is a ribonucleoside analogue that can inhibit the replication of many RNA viruses, including SARS-CoV-2. EIDD-2801 is the oral form of the antiviral compound EIDD-1931; it can be taken as a pill and can be properly absorbed before entering the lungs. Monabilavir is an oral drug that is activated by metabolism in the body. When it enters the cell, it is converted into RNA-like building blocks. In the first stage, a viral replication machine called RNA polymerase integrates this building block into the RNA genome of SARS-CoV-2. However, unlike Remdesivir, which delays viral RNA polymerase, monabiravir does not directly interfere with the function of this viral replication machine. On the contrary, in the second stage, this RNA-like building block is connected with the building block of the viral genetic material. The first author of the paper and a doctoral student in Cramer’s laboratory, Florian Kabiner, said, “When the viral RNAChemicalbook is subsequently copied to produce a new virus, it contains many errors, so-called mutations. The result is that the pathogen can no longer multiply.” The viral drug candidate molnupiravir (yellow) is integrated into the viral RNA, where it causes mutations (purple) and eventually prevents the virus from replicating. The picture is from MPIf.BiophysicalChemistry/FlorianKabinger, ChristianDienemannandPatrick. Monabilavir seems to also cause mutations in other RNA viruses, preventing them from spreading further. Höbartner said, "This compound has the potential to be used to treat many viral diseases. Monabilavir has great potential." Currently, this promising drug candidate is in phase 3 clinical studies, and it is in large numbers. Tested on patients. Whether monabiravir can be safely approved as a drug may be announced in the second half of this year. The US government is already very optimistic. It has recently received approximately 1.7 million doses of monabiravir, valued at more than $1 billion.